التفاصيل البيبلوغرافية
| العنوان: |
Outcomes of treatment of severe COVID-19 pneumonia with tocilizumab: a report of two cases from Tunisia. |
| المؤلفون: |
Ben Azaiz, Mouna1,2,3 drmouna1@yahoo.fr, Chatbri, Bassem2,4, Sellami, Walid2,5, Romdhani, Chihebeddine2,3,5, Lamine, Khaled2,4, Ghazouani, Ezzedine1, Oueslati, Ridha6, Gharsallah, Hedi2,3,5, Ferjani, Mustapha2,5 |
| المصدر: |
Pan African Medical Journal. Sep-Dec2021, Vol. 40, p1-6. 6p. |
| مصطلحات موضوعية: |
*COVID-19 pandemic, *COVID-19 treatment, *COVID-19, *THERAPEUTICS, *TOCILIZUMAB, *THYROID crisis |
| مصطلحات جغرافية: |
TUNISIA |
| مستخلص: |
The SARS CoV-2 pandemic is a global health threat with high morbidity and mortality (1 to 4%) rates. COVID-19 is correlated with important immune disorders, including a "cytokine storm". A new therapeutic approach using the immunomodulatory drug, Anti-IL6 (tocilizimub), has been proposed to regulate it. We report here the first Tunisian experience using tocilizimub in two severe cases of COVID-19 pneumonia. The diagnosis was confirmed by chest scan tomography. Biological parameters showed a high level of Interleukin-6 (IL-6) that increased significantly during hospitalization. The patients developed hypoxia, so they received intravenously 8 mg/kg body weight tocilizumab. There was a resultant decrease in the level of IL6, with clinically good evolution. Blocking the cytokine IL-6 axis is a promising therapy for patients developing COVID-19 pathology. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder